Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.62 |
| ▸ | MAOA | P21397 | 10/20 | 0.62 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 3/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496459 | 0.90 | MAOB (0.61) | MAOBMAOACREBBPNPC1ALDH1A1 | |
| SCHEMBL22369086 | 0.87 | MAOB (0.65) | MAOBMAOACREBBPNPC1ALDH1A1 | |
| SCHEMBL18794867 | 0.87 | MAOB (0.64) | MAOBMAOACREBBPNPC1GRM5 | |
| Water SCHEMBL2536819 | 0.84 | PARP1 (0.57) | MAOBMAOACREBBPNPC1ALDH1A1 | |
| SCHEMBL18794868 | 0.84 | MAOB (0.48) | MAOBMAOACREBBPNPC1GRM5 | |
| SCHEMBL18794870 | 0.84 | MAOB (0.48) | MAOBMAOACREBBPNPC1RAB9A | |
| SCHEMBL17673304 | 0.79 | CREBBP (0.80) | MAOBMAOACREBBPBRD4 | |
| SCHEMBL19518160 | 0.79 | CREBBP (0.80) | MAOBMAOACREBBPBRD4 | |
| SCHEMBL24508418 | 0.78 | PDE3B (0.57) | MAOBMAOACREBBPALDH1A1BRD4 | |
| SCHEMBL293145 | 0.78 | PDE3B (0.57) | MAOBMAOACREBBPALDH1A1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180312480-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-11-01 | — | — | US | claimed |
| EP-3371154-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | Trillium Therapeutics Inc. (CA) | 2018-09-12 | — | — | EP | claimed |
| WO-2017070796-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-05-04 | — | — | WO | claimed |
| US-6951855-B2 | Benzoxazinone derivatives for use in the treatment of angiogenesis | ASTRAZENECA AB (SE) | 2005-10-04 | — | — | US | claimed |
| US-20040122006-A1 | Benzoxazinone derivatives for use in the treatment of angiogenesis | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | US | claimed |
| EP-1385835-A1 | BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS | Astrazeneca AB (SE) | 2004-02-04 | — | — | EP | claimed |
| WO-2002085868-A1 | BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | claimed |
| WO-2021231933-A1 | ANTI-EPILEPTIC PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | NEUCYTE PHARMACEUTICALS (US) | 2021-11-18 | — | — | WO | disclosed |
| US-10428030-B2 | Heterocycle derivatives and their use for the treatment of CNS disorders | Trillium Therapeutics (CA) | 2019-10-01 | — | — | US | disclosed |
| US-10428030-B2 | Heterocycle derivatives and their use for the treatment of CNS disorders | Trillium Therapeutics (CA) | 2019-10-01 | — | — | US | disclosed |
| US-20180312480-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-11-01 | — | — | US | disclosed |
| EP-3371154-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | Trillium Therapeutics Inc. (CA) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017070796-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017070796-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | TRILLIUM THERAPEUTICS INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
| US-6951855-B2 | Benzoxazinone derivatives for use in the treatment of angiogenesis | ASTRAZENECA AB (SE) | 2005-10-04 | — | — | US | disclosed |
| US-20040122006-A1 | Benzoxazinone derivatives for use in the treatment of angiogenesis | ASTRAZENECA AB (SE) | 2004-06-24 | — | — | US | disclosed |
| EP-1385835-A1 | BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS | Astrazeneca AB (SE) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002085868-A1 | BENZOXAZINONE DERIVATIVES FOR USE IN THE TREATMENT OF ANGIOGENESIS | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312480-A1 | HETEROCYCLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, ACHE, CNR1 | MAOB 164/4885MAOA 264/4885CREBBP 125/4885 |
| US-20040122006-A1 | Benzoxazinone derivatives for use in the treatment of angiogenesis | HAX1, VEGFA, HYOU1 | MAOB 1050/4885MAOA 1737/4885CREBBP 2000/4885 |
| US-10428030-B2 | Heterocycle derivatives and their use for the treatment of CNS disorders | GRIN2C, ACHE, CNR1 | MAOB 164/4885MAOA 264/4885CREBBP 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.